483 related articles for article (PubMed ID: 21878451)
1. Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis.
Dalton CM; Bodini B; Samson RS; Battaglini M; Fisniku LK; Thompson AJ; Ciccarelli O; Miller DH; Chard DT
Mult Scler; 2012 Mar; 18(3):322-8. PubMed ID: 21878451
[TBL] [Abstract][Full Text] [Related]
2. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis.
Di Perri C; Battaglini M; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
Arch Neurol; 2008 Feb; 65(2):236-43. PubMed ID: 18268194
[TBL] [Abstract][Full Text] [Related]
3. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.
Masek M; Vaneckova M; Krasensky J; Danes J; Havrdova E; Hrebikova T; Seidl Z
Neuro Endocrinol Lett; 2008 Aug; 29(4):461-6. PubMed ID: 18766142
[TBL] [Abstract][Full Text] [Related]
4. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
[TBL] [Abstract][Full Text] [Related]
5. Lesion probability mapping to explain clinical deficits and cognitive performance in multiple sclerosis.
Kincses ZT; Ropele S; Jenkinson M; Khalil M; Petrovic K; Loitfelder M; Langkammer C; Aspeck E; Wallner-Blazek M; Fuchs S; Jehna M; Schmidt R; Vécsei L; Fazekas F; Enzinger C
Mult Scler; 2011 Jun; 17(6):681-9. PubMed ID: 21177325
[TBL] [Abstract][Full Text] [Related]
6. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
Sormani MP; Rovaris M; Comi G; Filippi M
Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
[TBL] [Abstract][Full Text] [Related]
7. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
Calabrese M; Rocca MA; Atzori M; Mattisi I; Favaretto A; Perini P; Gallo P; Filippi M
Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349
[TBL] [Abstract][Full Text] [Related]
8. Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study.
Ramasamy DP; Benedict RH; Cox JL; Fritz D; Abdelrahman N; Hussein S; Minagar A; Dwyer MG; Zivadinov R
J Neurol Sci; 2009 Jul; 282(1-2):47-54. PubMed ID: 19201003
[TBL] [Abstract][Full Text] [Related]
9. Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study.
Tedeschi G; Dinacci D; Comerci M; Lavorgna L; Savettieri G; Quattrone A; Livrea P; Patti F; Morra VB; Servillo G; Orefice G; Paciello M; Prinster A; Coniglio G; Bonavita S; Di Costanzo A; Bellacosa A; Valentino P; Quarantelli M; Brunetti A; Salemi G; D'Amelio M; Simone I; Salvatore M; Bonavita V; Alfano B
Mult Scler; 2009 Feb; 15(2):204-11. PubMed ID: 18987104
[TBL] [Abstract][Full Text] [Related]
10. Histogram analysis of diffusion measures in clinically isolated syndromes and relapsing-remitting multiple sclerosis.
Yu CS; Lin FC; Liu Y; Duan Y; Lei H; Li KC
Eur J Radiol; 2008 Nov; 68(2):328-34. PubMed ID: 17928182
[TBL] [Abstract][Full Text] [Related]
11. Conventional and magnetization transfer MRI predictors of clinical multiple sclerosis evolution: a medium-term follow-up study.
Rovaris M; Agosta F; Sormani MP; Inglese M; Martinelli V; Comi G; Filippi M
Brain; 2003 Oct; 126(Pt 10):2323-32. PubMed ID: 12937086
[TBL] [Abstract][Full Text] [Related]
12. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
Bates D
Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
[TBL] [Abstract][Full Text] [Related]
13. Association between MRI parameters and the MS severity scale: a 12 year follow-up study.
Minneboo A; Uitdehaag BM; Jongen P; Vrenken H; Knol Dl; van Walderveen MA; Polman CH; Castelijns JA; Barkhof F
Mult Scler; 2009 May; 15(5):632-7. PubMed ID: 19389751
[TBL] [Abstract][Full Text] [Related]
14. Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox?
Strasser-Fuchs S; Enzinger C; Ropele S; Wallner M; Fazekas F
Mult Scler; 2008 Mar; 14(2):205-11. PubMed ID: 17986507
[TBL] [Abstract][Full Text] [Related]
15. ADC measurements in various patterns of multiple sclerosis lesions.
Phuttharak W; Galassi W; Laopaiboon V; Laopaiboon M; Hesselink JR
J Med Assoc Thai; 2006 Feb; 89(2):196-204. PubMed ID: 16579006
[TBL] [Abstract][Full Text] [Related]
16. T2 lesions and rate of progression of disability in multiple sclerosis.
Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
[TBL] [Abstract][Full Text] [Related]
17. Deep grey matter T2 hypo-intensity in patients with paediatric multiple sclerosis.
Ceccarelli A; Rocca MA; Perego E; Moiola L; Ghezzi A; Martinelli V; Comi G; Filippi M
Mult Scler; 2011 Jun; 17(6):702-7. PubMed ID: 21228024
[TBL] [Abstract][Full Text] [Related]
18. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis.
Tauhid S; Neema M; Healy BC; Weiner HL; Bakshi R
J Neurol Sci; 2014 Nov; 346(1-2):250-4. PubMed ID: 25220114
[TBL] [Abstract][Full Text] [Related]
19. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
20. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
